CPRX vs. CL
CPRX (Catalyst Pharmaceuticals, Inc.) and CL (Colgate-Palmolive Company) are both stocks. CPRX operates in Biotechnology (Healthcare), while CL operates in Household & Personal Products (Consumer Defensive). Over the past 10 years, CPRX returned 44.45%/yr vs 5.07%/yr for CL. At a 0.08 correlation, their price movements are largely independent.
Performance
CPRX vs. CL - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CPRX achieves a 34.53% return, which is significantly higher than CL's 17.14% return. Over the past 10 years, CPRX has outperformed CL with an annualized return of 44.45%, while CL has yielded a comparatively lower 5.07% annualized return.
CPRX
- 1D
- 0.06%
- 1M
- 0.45%
- YTD
- 34.53%
- 6M
- 29.59%
- 1Y
- 41.95%
- 3Y*
- 33.66%
- 5Y*
- 39.71%
- 10Y*
- 44.45%
CL
- 1D
- 3.11%
- 1M
- 0.90%
- YTD
- 17.14%
- 6M
- 15.80%
- 1Y
- 5.72%
- 3Y*
- 8.37%
- 5Y*
- 5.03%
- 10Y*
- 5.07%
CPRX vs. CL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CPRX Catalyst Pharmaceuticals, Inc. | 34.53% | 11.84% | 24.15% | -9.62% | 174.74% | 102.69% | -10.93% | 95.31% | -50.90% | 272.38% |
CL Colgate-Palmolive Company | 17.14% | -10.98% | 16.57% | 3.78% | -5.44% | 2.08% | 27.17% | 18.60% | -19.19% | 17.88% |
Correlation
The correlation between CPRX and CL is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.11 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.08 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.10 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.10 |
Correlation (All Time) Calculated using the full available price history since Nov 8, 2006 | 0.08 |
Fundamentals
CPRX:
$3.98B
CL:
$73.61B
CPRX:
$1.74
CL:
$2.58
CPRX:
18.05
CL:
35.45
CPRX:
0.32
CL:
9.16
CPRX:
6.69
CL:
3.56
CPRX:
3.93
CL:
507.66
CPRX:
$596.96M
CL:
$20.80B
CPRX:
$378.23M
CL:
$12.49B
CPRX:
$313.50M
CL:
$3.92B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CPRX vs. CL — Risk / Return Rank
CPRX
CL
CPRX vs. CL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and Colgate-Palmolive Company (CL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CPRX | CL | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.03 | ||
| Sortino ratioReturn per unit of downside risk | +1.32 | ||
| Omega ratioGain probability vs. loss probability | 1.25 | 1.06 | +0.19 |
| Calmar ratioReturn relative to maximum drawdown | 3.03 | 0.31 | +2.72 |
| Martin ratioReturn relative to average drawdown | 7.92 | 0.50 | +7.42 |
Loading charts...
Drawdowns
CPRX vs. CL - Drawdown Comparison
The maximum CPRX drawdown since its inception was -94.25%, which is greater than CL's maximum drawdown of -58.91%. Use the drawdown chart below to compare losses from any high point for CPRX and CL.
Loading charts...
Drawdown Indicators
| CPRX | CL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.25% | -58.91% | -35.34% |
Max Drawdown (1Y)Largest decline over 1 year | -13.91% | -18.64% | +4.73% |
Max Drawdown (3Y)Largest decline over 3 years | -27.29% | -29.05% | +1.76% |
Max Drawdown (5Y)Largest decline over 5 years | -45.37% | -29.05% | -16.32% |
Max Drawdown (10Y)Largest decline over 10 years | -64.87% | -29.05% | -35.82% |
Current DrawdownCurrent decline from peak | 0.00% | -12.41% | +12.41% |
Average DrawdownAverage peak-to-trough decline | -51.90% | -11.24% | -40.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.32% | 11.38% | -6.06% |
Volatility
CPRX vs. CL - Volatility Comparison
The current volatility for Catalyst Pharmaceuticals, Inc. (CPRX) is 0.46%, while Colgate-Palmolive Company (CL) has a volatility of 8.77%. This indicates that CPRX experiences smaller price fluctuations and is considered to be less risky than CL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CPRX | CL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 0.46% | 8.77% | -8.31% |
Volatility (6M)Calculated over the trailing 6-month period | 22.84% | 17.30% | +5.54% |
Volatility (1Y)Calculated over the trailing 1-year period | 32.65% | 21.81% | +10.84% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 47.79% | 18.85% | +28.94% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 60.09% | 19.77% | +40.32% |
Dividends
CPRX vs. CL - Dividend Comparison
CPRX has not paid dividends to shareholders, while CL's dividend yield for the trailing twelve months is around 2.29%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CL Colgate-Palmolive Company | 2.29% | 2.61% | 2.18% | 2.40% | 2.36% | 2.10% | 2.05% | 2.48% | 2.79% | 2.11% | 2.37% | 2.25% |
CPRX Catalyst Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
CPRX vs. CL - Financials Comparison
This section allows you to compare key financial metrics between Catalyst Pharmaceuticals, Inc. and Colgate-Palmolive Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CPRX vs. CL - Profitability Comparison
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.
CL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Colgate-Palmolive Company reported a gross profit of 3.23B and revenue of 5.32B. Therefore, the gross margin over that period was 60.6%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.
CL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Colgate-Palmolive Company reported an operating income of 1.16B and revenue of 5.32B, resulting in an operating margin of 21.7%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.
CL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Colgate-Palmolive Company reported a net income of 646.00M and revenue of 5.32B, resulting in a net margin of 12.1%.
Frequently Asked Questions
CPRX and CL have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CL has higher volatility (8.77%) compared to CPRX (0.46%). In terms of maximum drawdown, CPRX dropped -94.25% vs CL's -58.91%.
CPRX currently has the higher Sharpe Ratio (1.29 vs 0.26), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CPRX and CL
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer